Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Latest in bladder cancer from the second half of 2025

ESMO 2025

17 - 21 Oct 2025

Published: 25 Nov 2025

Views: 106

Rating:

Save

Dr Alison Birtle, Dr Ignacio Durán, Prof Evanguelos Xylinas, Dr Giuseppe Simone and Dr Enrique Grande

Dr Alison Birtle (Lancashire Teaching Hospitals, UK), Dr Ignacio Durán (Marques de Valdecilla University Hospital, Spain), Prof Evanguelos Xylinas (Bichat-Claude Bernard Hospital, France), Dr Giuseppe Simone (Regina Elena National Cancer Institute, Italy) and Dr Enrique Grande (University Hospital Quironsalud Madrid, Madrid, Spain) discuss the latest updates in bladder cancer treatment for the second half of 2025.

	Thinking outside the box: Novel or unexpected data
	Latest in NMIBC
	Advanced disease in bladder cancer
	Updates in the perioperative setting
	Take home messages

Related Videos

PRAME-targeted TCR therapy shows high response rates in metastatic uveal...

Dr Sapna Patel - University of Colorado Anschutz, Aurora, USA

PRAME-targeted TCR therapy shows high response rates in metastatic uveal melanoma ( Dr Sapna Patel - University of Colorado Anschutz, Aurora, USA )

ESMO 2025: Latest in mRCC

Dr Javier Puente, Prof Jens Bedke, Prof Laurence Albiges and Prof Viktor...

ESMO 2025: Latest in mRCC ( Dr Javier Puente, Prof Jens Bedke, Prof Laurence Albiges and Prof Viktor Grünwald )

Best practice in precision medicine for prostate cancer

Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich

Best practice in precision medicine for prostate cancer ( Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich )

Bladder cancer updates from the first half of 2025

Dr Alison Birtle, Dr Ignacio Durán, Prof Evanguelos Xylinas, Dr Giuseppe Simone...

Bladder cancer updates from the first half of 2025 ( Dr Alison Birtle, Dr Ignacio Durán, Prof Evanguelos Xylinas, Dr Giuseppe Simone and Dr Benjamin Pradere )

Darolutamide plus ADT provides deep and durable PSA responses in metastatic...

Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada

Darolutamide plus ADT provides deep and durable PSA responses in metastatic hormone-sensitive prostate cancer ( Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada )

EAU 2025: Updates in NMIBC

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Alexandra Masson-Lecomte and...

EAU 2025: Updates in NMIBC ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Alexandra Masson-Lecomte and Dr Giuseppe Simone )

ASCO GU 2025: Latest updates in mRCC

Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto...

ASCO GU 2025: Latest updates in mRCC ( Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto Iacovelli )

Understanding the use of PARPi combinations to treat patients with mCRPC

Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof...

Understanding the use of PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard )

Durable responses in aRCC, how do we optimise treatment?

Prof Roberto Iacovelli and Prof Viktor Grünwald

Durable responses in aRCC, how do we optimise treatment? ( Prof Roberto Iacovelli and Prof Viktor Grünwald )

More from ecancer